Download BayeraspirinHCP.com

BAYER Aspirin
®
Analgesic properties
Anti-inflammatory properties
T
Antipyretic properties
Antiplatelet properties
The Wonder Drug
®
Now More Than Ever
For free patient samples, click here: bayeraspirinhcp.com
BAYER Aspirin
®
A Powerful Combination of Properties
Aspirin is one of the most versatile drugs ever discovered. It
is also one of the most extensively studied medications, with
several new clinical trials across numerous therapeutic areas
currently underway.1-5
Aspirin also has the power to relieve pain and even
temporarily alleviate fevers from colds.5,6 This is possible
because aspirin’s combination of properties includes:
Analgesic
n Anti-inflammatory
n
Antipyretic
n Antiplatelet
n
B AYER A sp irin : The Wond er D ru g®
T
T
Aspirin can help save a life during a suspected heart attack
and can lower the risk of secondary cardiovascular (CV) events.
BAYER Aspirin
®
The Original Analgesic
Aspirin has long been known for its analgesic properties. Overstimulated tissue produces
prostaglandins, which in turn produce inflammation and pain. Aspirin interrupts this process
by inhibiting prostaglandin production, thereby reducing inflammation and alleviating pain.4
Because of its analgesic properties, aspirin can be used for the temporary relief of 6:
Headache
n Toothache
Muscle pain
n Menstrual pain
n
Pain and fever of colds
n Minor pain of arthritis
n
Aspirin is also indicated for the relief of 5:
Rheumatoid arthritis (RA)
n Juvenile rheumatoid arthritis (JRA)
n Osteoarthritis (OA)
n Spondyloarthropathies
n Arthritis and pleurisy associated with
systemic lupus erythematosus (SLE)
n
B AYER A sp irin : The Wond er D ru g®
T
T
n
BAYER Aspirin
®
Antipyretic Relief
Patients experience a fever when concentrations of prostaglandin E2 (PGE2) increase
within certain areas of the brain. These elevations alter the firing rate of neurons that
control thermoregulation in the hypothalamus.7 By inhibiting prostaglandin production,
aspirin exerts an antipyretic effect that temporarily alleviates fevers.4
Aside from its antipyretic benefits, patients with the common cold can take aspirin to
help relieve4,6:
Headache
n Body aches
n Sore throat pain
B AYER A sp irin : The Wond er D ru g®
T
T
n
BAYER Aspirin
®
Antiplatelet for CV Event Prevention
Aspirin is a more potent inhibitor of platelet aggregation than other salicylic acid derivatives.
Aspirin affects platelet aggregation by irreversibly inhibiting prostaglandin cyclo-oxygenase-1 (COX-1).
This effect lasts for the life of the platelet and prevents the formation of the platelet aggregating
factor thromboxane A2 (TXA2).5 This powerful antiplatelet is clinically proven to help prevent CV
events and continues to be highly recommended as a first-line therapy.8-11
Aspirin is recognized as a first-line (Class 1/Grade 1A level)
therapy, higher than other treatments, by the following
professional organizations:
AHA/ASA—Class 1, Level of Evidence A recommendation
n AHA/ACC—Grade 1A recommendation
n AHA/ACCF—Class 1, Level of Evidence A recommendation
n ACCP—Class 1, Level of Evidence A recommendation
n
B AYER A sp irin : The Wond er D ru g®
AHA=American Heart Association; ASA=American Stroke Association; ACC=American College of Cardiology;
ACCF=American College of Cardiology Foundation; ACCP=American College of Chest Physicians.
T
T
Major CV guidelines recommend aspirin as a first-line treatment for the secondary prevention
of CV events8-11
BAYER Aspirin
®
Antiplatelet for Secondary MI Prevention
In the United States, 700,000 people experience an MI each year; of these cases, 210,000
are recurrent MIs.12 Aspirin is proven to help protect patients who have suffered an MI:
31%
13*
Patients who discontinue
low-dose aspirin can increase
their risk of MI by
63%
14
T
T
Aspirin is proven to reduce
the risk of recurrent MI by
While patients can take aspirin on its own, it is also recommended as an adjunctive therapy for
many prescription antiplatelets, including 15-17:
Plavix® (clopidogrel bisulfate)
Brilinta® (ticagrelor)
Effient® (prasugrel)
B AYER A sp irin : The Wond er D ru g®
*Nonfatal MI.
MI=myocardial infarction.
BAYER Aspirin
®
Antiplatelet for Secondary Ischemic Stroke Prevention
In the United States, more than 690,000 people experience an ischemic stroke each year.
Of these cases, 210,000 are recurrent strokes.12 Aspirin remains the most studied and widely
used antiplatelet for the secondary prevention of stroke.4
22%
13
Patients who discontinue lowdose aspirin can increase their
risk of ischemic stroke by
40%
18
T
T
Aspirin is proven to reduce
the risk of recurrent
ischemic stroke by
A combination of 5 factors, including aspirin, can result in an 80% cumulative risk reduction
of recurrent ischemic stroke 19:
Aspirin regimen
Dietary modification
Regular exercise
Statin therapy
Antihypertensive therapy
B AYER A sp irin : The Wond er D ru g®
BAYER Aspirin
®
Professional Indications
5
Aspirin is indicated:
1. To reduce the combined risk of death and nonfatal stroke in patients who have had ischemic
stroke or transient ischemia of the brain due to fibrin platelet emboli
2. To reduce the risk of vascular mortality in patients with suspected acute MI
4. To reduce the combined risk of MI and sudden death in patients
with chronic stable angina pectoris
5. In patients who have undergone revascularization procedures
(ie, coronary artery bypass graft [CABG], percutaneous
transluminal coronary angioplasty [PTCA], or carotid
endarterectomy [CEA]) when there is a preexisting condition
for which aspirin is already indicated
B AYER A sp irin : The Wond er D ru g®
T
T
3. To reduce the combined risk of death and nonfatal MI in patients with a previous MI or
unstable angina pectoris
BAYER Aspirin
®
Prescribing Information
5
Each dose of aspirin should be taken with a full glass of water, unless the patient is fluid
restricted. Anti-inflammatory and analgesic dosages should be individualized. When aspirin is
used in high doses, the development of tinnitus may be used as a clinical sign of elevated plasma
salicylate levels, except in patients with high-frequency hearing loss.
Suspected Acute MI
The initial dose of 160-162.5 mg is administered as soon as an MI is suspected. The maintenance dose
of 160-162.5 mg a day is continued for 30 days post-infarction. After 30 days, consider further therapy
based on dosage and administration for prevention of recurrent MI.
Prevention of Recurrent MI
75-325 mg once a day. Continue therapy indefinitely.
Unstable Angina Pectoris
75-325 mg once a day. Continue therapy indefinitely.
Chronic Stable Angina Pectoris
75-325 mg once a day. Continue therapy indefinitely.
Coronary Artery Bypass Graft
325 mg daily, starting 6 hours post-procedure. Continue therapy for 1 year post-procedure.
Percutaneous Transluminal Coronary Angioplasty
The initial dose of 325 mg should be given 2 hours pre-surgery. The maintenance dose
is 160-325 mg daily. Continue therapy indefinitely.
B AYER A sp irin : The Wond er D ru g®
T
T
Ischemic Stroke and Transient Ischemic Attack (TIA)
50-325 mg once a day. Continue therapy indefinitely.
BAYER Aspirin
®
Prescribing Information (cont’d)
5
Carotid Endarterectomy
Doses of 80 mg once daily to 650 mg twice daily, starting pre-surgery, are recommended.
Continue therapy indefinitely.
Juvenile Rheumatoid Arthritis
The initial dose is 90-130 mg/kg a day in divided doses. Increase as needed for anti-inflammatory
efficacy with target plasma salicylate levels of 150-300 mcg/mL. At high doses (ie, plasma levels of
greater than 200 mcg/mL), the incidence of toxicity increases.
Spondyloarthropathies
Up to 4 g a day in divided doses.
Osteoarthritis
Up to 3 g a day in divided doses.
Arthritis and Pleurisy of Systemic Lupus Erythematosus
The initial dose is 3 g a day in divided doses. Increase as needed for anti-inflammatory efficacy with
target plasma salicylate levels of 150-300 mcg/mL. At high doses (ie, plasma levels of greater than
200 mcg/mL), the incidence of toxicity increases.
B AYER A sp irin : The Wond er D ru g®
T
T
Rheumatoid Arthritis
The initial dose is 3 g a day in divided doses. Increase as needed for anti-inflammatory efficacy
with target plasma salicylate levels of 150-300 mcg/mL. At high doses (ie, plasma levels of
greater than 200 mcg/mL), the incidence of toxicity increases.
BAYER Aspirin
®
The Clinical Trials Continue
Aspirin has been studied alone and in combination with a wide range of drugs and for
numerous conditions.5 There are many clinical trials currently underway, including, but
not limited to 1-3:
A Study of Cardiovascular Events in Diabetes (ASCEND)
n Aspirin in Reducing Events in the Elderly (ASPREE)
n A Study to Assess the Efficacy and Safety of Enteric-coated Acetylsalicylic Acid in Patients
at Moderate Risk of Cardiovascular Disease (ARRIVE)
We are still learning a lot about the powerful properties of aspirin, and we hope to continue
finding even more reasons to love BAYER Aspirin, The Wonder Drug®.
For free patient samples, click here: bayeraspirinhcp.com
B AYER A sp irin : The Wond er D ru g®
T
T
n
BAYER Aspirin
®
References:
1. University of Oxford Clinical Trial Service Unit. ASCEND trial website. https://ascend.medsci.ox.ac.uk/about. Accessed February 7, 2017.
2. ASPirin in Reducing Events in the Elderly. ASPREE trial website. http://www.aspree.org/usa/. Accessed December 7, 2016.
3. US National Library of Medicine. ARRIVE trial. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT00501059?term=ARRIVE+Aspirin&rank=1.
Accessed December 7, 2016.
4. Data on file. Bayer.
5. Aspirin Prescribing Information. Morristown, NJ: Bayer Corporation.
6. Genuine BAYER Aspirin Tablets. BAYER Aspirin website. Available at https://www.wonderdrug.com/products/genuine-bayer-aspirin/. Published May 2014.
Accessed December 7, 2016.
7. Aronoff DM, Neilson EG. Antipyretics: mechanisms of action and clinical use in fever suppression. Am J Med. 2001;111(4):304-315.
T
8. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for
healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–2236.
9. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes:
a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.
10. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O’Gara PT, et al. 2013 ACCF/AHA guideline for the
management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140.
11. Lansberg MG, O’Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e601S-e636S.
12. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation.
2015;131:e29-e322.
13. Antithrombotic Trialists’ (ATT) Collaboration. Lancet. 2009;373:1849-1860.
14. García Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study
in UK primary care. BMJ. 2011;343:d4094.
15. Plavix® (clopidogrel bisulfate) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2015.
16. Brilinta® (ticagrelor) [prescribing information]. Wilmington, DE: AstraZeneca LP; 2015.
17. Effient® (prasugrel) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2015.
18. García Rodríguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Neurology. 2011;76:740-746.
19. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke.
2007;38(6):1881-1885.
B AYER A sp irin : The Wond er D ru g®
Bayer, the Bayer Cross, and The Wonder Drug are registered trademarks of Bayer. All other trademarks are the property of their respective owners.
© 2017 Bayer January 2017 PP-BAY-PREV-US-0648
BAYER Aspirin
®
Antiplatelet for CV Event Prevention
Aspirin is a more potent inhibitor of platelet aggregation than other salicylic acid derivatives.
Aspirin affects platelet aggregation by irreversibly inhibiting prostaglandin cyclo-oxygenase-1 (COX-1).
This effect lasts for the life of the platelet and prevents the formation of the platelet aggregating
factor thromboxane A2 (TXA2).5 This powerful antiplatelet is clinically proven to help prevent CV
events and continues to be highly recommended as a first-line therapy.8-11
Aspirin is recognized as a first-line (Class 1/Grade 1A level)
therapy, higher than other treatments, by the following
professional organizations:
AHA/ASA—Class 1, Level of Evidence A recommendation
n AHA/ACC—Grade 1A recommendation
n AHA/ACCF—Class 1, Level of Evidence A recommendation
n ACCP—Class 1, Level of Evidence A recommendation
n
B AYER A sp irin : The Wond er D ru g®
AHA=American Heart Association; ASA=American Stroke Association; ACC=American College of Cardiology;
ACCF=American College of Cardiology Foundation; ACCP=American College of Chest Physicians.
T
T
Major CV guidelines recommend aspirin as a first-line treatment for the secondary prevention
of CV events8-11
BAYER Aspirin
®
Antiplatelet for CV Event Prevention
Aspirin is a more potent inhibitor of platelet aggregation than other salicylic acid derivatives.
Aspirin affects platelet aggregation by irreversibly inhibiting prostaglandin cyclo-oxygenase-1 (COX-1).
This effect lasts for the life of the platelet and prevents the formation of the platelet aggregating
factor thromboxane A2 (TXA2).5 This powerful antiplatelet is clinically proven to help prevent CV
events and continues to be highly recommended as a first-line therapy.8-11
Aspirin is recognized as a first-line (Class 1/Grade 1A level)
therapy, higher than other treatments, by the following
professional organizations:
AHA/ASA—Class 1, Level of Evidence A recommendation
n AHA/ACC—Grade 1A recommendation
n AHA/ACCF—Class 1, Level of Evidence A recommendation
n ACCP—Class 1, Level of Evidence A recommendation
n
B AYER A sp irin : The Wond er D ru g®
AHA=American Heart Association; ASA=American Stroke Association; ACC=American College of Cardiology;
ACCF=American College of Cardiology Foundation; ACCP=American College of Chest Physicians.
T
T
Major CV guidelines recommend aspirin as a first-line treatment for the secondary prevention
of CV events8-11
BAYER Aspirin
®
Antiplatelet for CV Event Prevention
Aspirin is a more potent inhibitor of platelet aggregation than other salicylic acid derivatives.
Aspirin affects platelet aggregation by irreversibly inhibiting prostaglandin cyclo-oxygenase-1 (COX-1).
This effect lasts for the life of the platelet and prevents the formation of the platelet aggregating
factor thromboxane A2 (TXA2).5 This powerful antiplatelet is clinically proven to help prevent CV
events and continues to be highly recommended as a first-line therapy.8-11
Aspirin is recognized as a first-line (Class 1/Grade 1A level)
therapy, higher than other treatments, by the following
professional organizations:
AHA/ASA—Class 1, Level of Evidence A recommendation
n AHA/ACC—Grade 1A recommendation
n AHA/ACCF—Class 1, Level of Evidence A recommendation
n ACCP—Class 1, Level of Evidence A recommendation
n
B AYER A sp irin : The Wond er D ru g®
AHA=American Heart Association; ASA=American Stroke Association; ACC=American College of Cardiology;
ACCF=American College of Cardiology Foundation; ACCP=American College of Chest Physicians.
T
T
Major CV guidelines recommend aspirin as a first-line treatment for the secondary prevention
of CV events8-11
BAYER Aspirin
®
Antiplatelet for CV Event Prevention
Aspirin is a more potent inhibitor of platelet aggregation than other salicylic acid derivatives.
Aspirin affects platelet aggregation by irreversibly inhibiting prostaglandin cyclo-oxygenase-1 (COX-1).
This effect lasts for the life of the platelet and prevents the formation of the platelet aggregating
factor thromboxane A2 (TXA2).5 This powerful antiplatelet is clinically proven to help prevent CV
events and continues to be highly recommended as a first-line therapy.8-11
Aspirin is recognized as a first-line (Class 1/Grade 1A level)
therapy, higher than other treatments, by the following
professional organizations:
AHA/ASA—Class 1, Level of Evidence A recommendation
n AHA/ACC—Grade 1A recommendation
n AHA/ACCF—Class 1, Level of Evidence A recommendation
n ACCP—Class 1, Level of Evidence A recommendation
n
B AYER A sp irin : The Wond er D ru g®
AHA=American Heart Association; ASA=American Stroke Association; ACC=American College of Cardiology;
ACCF=American College of Cardiology Foundation; ACCP=American College of Chest Physicians.
T
T
Major CV guidelines recommend aspirin as a first-line treatment for the secondary prevention
of CV events8-11
BAYER Aspirin
®
The Clinical Trials Continue
Aspirin has been studied alone and in combination with a wide range of drugs and for
numerous conditions.5 There are many clinical trials currently underway, including, but
not limited to 1-3:
A Study of Cardiovascular Events in Diabetes (ASCEND)
n Aspirin in Reducing Events in the Elderly (ASPREE)
n A Study to Assess the Efficacy and Safety of Enteric-coated Acetylsalicylic Acid in Patients
at Moderate Risk of Cardiovascular Disease (ARRIVE)
We are still learning a lot about the powerful properties of aspirin, and we hope to continue
finding even more reasons to love BAYER Aspirin, The Wonder Drug®.
For free patient samples, click here: bayeraspirinhcp.com
B AYER A sp irin : The Wond er D ru g®
T
T
n
BAYER Aspirin
®
The Clinical Trials Continue
Aspirin has been studied alone and in combination with a wide range of drugs and for
numerous conditions.5 There are many clinical trials currently underway, including, but
not limited to 1-3:
A Study of Cardiovascular Events in Diabetes (ASCEND)
n Aspirin in Reducing Events in the Elderly (ASPREE)
n A Study to Assess the Efficacy and Safety of Enteric-coated Acetylsalicylic Acid in Patients
at Moderate Risk of Cardiovascular Disease (ARRIVE)
We are still learning a lot about the powerful properties of aspirin, and we hope to continue
finding even more reasons to love BAYER Aspirin, The Wonder Drug®.
For free patient samples, click here: bayeraspirinhcp.com
B AYER A sp irin : The Wond er D ru g®
T
T
n
BAYER Aspirin
®
The Clinical Trials Continue
Aspirin has been studied alone and in combination with a wide range of drugs and for
numerous conditions.5 There are many clinical trials currently underway, including, but
not limited to 1-3:
A Study of Cardiovascular Events in Diabetes (ASCEND)
n Aspirin in Reducing Events in the Elderly (ASPREE)
n A Study to Assess the Efficacy and Safety of Enteric-coated Acetylsalicylic Acid in Patients
at Moderate Risk of Cardiovascular Disease (ARRIVE)
We are still learning a lot about the powerful properties of aspirin, and we hope to continue
finding even more reasons to love BAYER Aspirin, The Wonder Drug®.
For free patient samples, click here: bayeraspirinhcp.com
B AYER A sp irin : The Wond er D ru g®
T
T
n